Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

United Therapeutics Corp Del (UTHR)

843 + Investors. Track Smart Money conviction in UTHR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +26
Streak
4Q ▲
Buyers last Q
50%

Smart Money Signals — UTHR

Based on 851 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added UTHR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
851 hedge funds hold UTHR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +30% more funds vs a year ago

fund count last 6Q
+196 new funds entered over the past year (+30% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 50% buying

422 buying426 selling
Last quarter: 422 funds bought or added vs 426 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-78 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 85 → 114 → 200 → 122. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 22% medium ■ 26% new
442 out of 851 hedge funds have held UTHR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +21% but shares only +3% — price-driven

Value
+21%
Shares
+3%
Last quarter: the total dollar value of institutional holdings rose +21%, but actual share count only changed +3%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

90 → 85 → 114 → 200 → 122 new funds/Q
New funds entering each quarter: 85 → 114 → 200 → 122. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 59% veterans vs 29% newcomers

■ 59% veterans ■ 12% 1-2yr ■ 29% new
Entry-cohort mix of 885 holders: 520 (59%) are 2+ year veterans, 104 entered 1–2 years ago, and 261 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 39% AUM from major funds

39% from top-100 AUM funds
61 of 844 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — UTHR

In 2026 Q1, 422 hedge funds were net buyers of UTHR (122 opened a new position, 300 added to an existing one), while 426 reduced or exited (330 trimmed, 96 sold completely) — a 50% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 39% of total institutional value in UTHR is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +26 funds (more new holders than closures). Total institutional holders: 851.

Hedge Fund Ownership: UTHR

How many hedge funds hold UTHR — quarterly history vs. share price
Quarterly hedge fund ownership of UTHR vs. share price

Market Analysis: UTHR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: UTHR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy United Therapeutics Corp Del (UTHR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much UTHR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
UTHR
-7.5%
XLV
+4.3%

UTHR outperformed XLV by -11.8% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
UTHR
-3.6%
XLV
+5.4%

Since the filing became public, UTHR outperformed XLV by -9.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

52 top-rated funds 13 high-conviction
Consensus
7.5
/ 10
breadth
×
Elite
5.1
/ 10
conviction
Hedge Fund Positioning: UTHR
843 + Investors

Track Smart Money conviction in UTHR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 843 825 2.18%
13F Shares 45M 43M 3.37%
Total Value $25.04B $20.64B 21.33%
New Positions 118 200 -82
Increased Positions 294 273 +21
Closed Positions 100 73 +27
Reduced Positions 317 258 +59
Total Calls 20 11 81.82%
Total Puts 21 12 75.0%
PUT/CALL Ratio 1.05 1.09 Neutral

Statistics: UTHR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

843 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in UTHR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 UTHR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Avoro Capital Advisors LLC 15.34% 2,630,000 $1.56B
2 Nepsis Inc. 8.38% 42,194 $25.0M
3 Eversept Partners, LP 8.26% 264,271 $156.7M
4 First Turn Management, LLC 6.94% 104,726 $62.1M
5 Nitorum Capital, L.P. 5.97% 11,464 $6.8M
6 Tri Locum Partners LP 5.86% 70,370 $41.7M
7 Palo Alto Investors LP 5.70% 62,809 $37.2M
8 Summit Street Capital Management, LLC 4.77% 56,872 $33.7M
9 Polaris Capital Management, LLC 4.69% 96,650 $57.3M
10 Soleus Capital Management, L.P. 4.50% 187,187 $111.0M
11 Diadema Partners LP 4.06% 40,200 $23.8M
12 Ardsley Advisory Partners LP 3.78% 50,000 $29.6M
13 Sofinnova Investments, Inc. 3.61% 160,070 $94.9M
14 Illumine Investment Management, LLC 3.53% 7,735 $4.6M
15 Deerfield Management Company, L.P. 3.20% 457,000 $271.0M
16 Resolute Capital Asset Partners LLC 3.12% 10,000 $5.9M
17 Seizert Capital Partners, LLC 2.86% 104,667 $62.1M
18 Diadema Partners LP 2.75% 27,303 $16.2M
19 Elmind Capital, LP 2.53% 15,000 $8.9M
20 Sidoxia Capital Management, LLC 2.50% 4,886 $2.9M
21 PFM Health Sciences, LP 2.48% 45,900 $27.2M
22 Logos Global Management LP 2.37% 80,000 $47.4M
23 Caption Management, LLC 2.31% 667,200 $395.6M
24 Sawgrass Asset Management LLC 2.24% 25,109 $14.9M
25 Superstring Capital Management LP 2.20% 5,186 $3.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — United Therapeutics Corp Del (UTHR)

What does the Smart Money Trend signal show for UTHR?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added UTHR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for UTHR?

Slight buying edge — 50% buying: Last quarter: 422 funds bought or added vs 426 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for UTHR holders?

Strong quality — 39% AUM from major funds: 61 of 844 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held UTHR?

52% of holders stayed for 2+ years: 442 out of 851 hedge funds have held UTHR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy United Therapeutics Corp Del (UTHR) following the 2026 Q1 hedge fund 13F filings?

As of today, UTHR has moved -3.6% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of -9.0%. Since the quarter end (March 31, 2026), UTHR has gained -7.5% vs +4.3% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →